Fast Five Quiz: Type 2 Diabetes in the Intensive Care Setting

Anne L. Peters, MD

Disclosures

January 25, 2022

In the NICE-SUGAR trial, critically ill patients with diabetes were randomized to intensive glycemic control (80-110 mg/dL) or moderate glycemic control (140-180 mg/dL). The study found no significant treatment advantage among patients in the intensive control arm vs the moderate control cohort. In fact, slightly but significantly higher mortality rates (27.5% vs 25%) were associated with more intensive glucose control. The intensively treated cohort also had 10 to 15-fold greater rates of hypoglycemia, which may have contributed to the increase in mortality.

Learn more about the management of type 2 diabetes in different settings.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....